Dendreon Corporation has announced that the European Commission (EC) has granted marketing authorization on 17 September 2013 for Provenge (autologous...
Marie Huber in a paper in the Journal of the National Cancer Institute argues that Provenge (sipuleucel-T)from Dendreon extended survival...
Dendreon Pharmaceuticals announced publication of an analysis examining real-world survival outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC) who were treated with Provenge (sipuleucel-T) and commonly prescribed oral treatments.
The National Institute for Health and Care Excellence (NICE) has decided not to recommend Provenge (sipuleucel-T) from Dendreon for the...
Dendreon will reduce its workforce by 500 employees( about one-quarter of its work force)as sales of its prostate cancer immunotherapy,...
Valeant Pharmaceuticals International, Inc. announced that it has entered into a "stalking horse" asset purchase agreement to acquire certain assets...
Dendreon Corporation announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has on 28...
Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.
Valeant Pharmaceuticals International, Inc. has announced that its affiliate has entered into a definitive agreement to sell all of the...
Dendreon Corporation has announced that it has reached agreements on the terms of a financial restructuring with certain holders of...